A technique that thwarts tumour camouflage
The newspaper El País has published an article about a scientific study that reveals that immunotherapy with antibodies prevents cancer from evading natural killer cells. The article includes statements by Eduard Batlle, head of the Colorectal Cancer Lab at IRB Barcelona, as an external expert.
Link to El País
Related content
News
These proteins are a potential therapeutic target for enhancing the effect of some cancer treatments.
Inhibition of TLK proteins triggers the Alternative Lengthening of Telomeres pathway, a common process in some of the most aggressive types of cancer, such as glioblastoma.
The study, performed by the Genomic Instability and Cancer Laboratory at IRB Barcelona, has been published in the journal Cell Reports.
The mechanism unveiled triggers a mutation fog, causing hundreds of mutations in each tumor, which spread through the genome of lung, head-and-neck and breast cancers.
Researchers from the Genome Data Science Lab have identified the antiviral APOBEC3A enzyme as the major cause of this new type of hypermutation.
Published in Nature Genetics, the study shows how the mutation fog process generates many oncogenic “cancer driver” mutations, thus accelerating tumour development.
Clara Morral is the first author of an article recently published in the scientific journal Cell Stem Cell.
The study identifies that protein synthesis is a key property for the regenerative potential of colon cancer cells.
